Request for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response
- Client
- Department of Health and Human Services
- RFP Number
- MEDI-8015
- Posted
- —
- Category
- Medical Services
- Budget
- Looking for Proposals
- NAICS
- 541714
- Set-aside
- No Set aside used
- Contact
- Laura Saddison
Description
AI GeneratedThe buyer requires a vendor to provide a vaccine medical countermeasures service in Washington, DC. Under this five-year contract, the selected vendor must supply medical countermeasures, including vaccines, antigens, and adjuvants, for pandemic preparedness and response or as required during a public health emergency. The vendor must produce antigens and vaccines against the influenza virus or other viruses with pandemic potential. Additionally, the vendor must produce antigens, vaccines, and adjuvants to support efforts to further improve influenza vaccines. Only United States organizations are eligible to participate in this opportunity. The vendor may perform the requested work either onsite or offsite. The buyer is currently seeking proposals and accepts digital submissions via email or online. Interested bidders must submit all questions regarding this opportunity no later than August 31, 2026.
Key solicitation details
AI-extracted from 19_75A50126R0001_RFP Att 19 Surge Manufacturing and Supply Chain Readiness Assessment.pdf, 18-75A50126R00001_RFP Att 18 BCP SCP Continuity Plans.pdf, 17-75A50126R00001_RFP Att 17 Manufacturing Plan.pdf. Confirm against the original documents before bidding.
The buyer is procuring vaccine medical countermeasures (MCMs), including vaccines, antigens, and adjuvants, for pandemic preparedness, response, and influenza vaccine improvements. The contract duration is five years, and eligible bidders are onshore USA organizations only.
- Issued by
- BARDA
- Questions due
- August 31, 2026
- How to submit
- Digital via Email or Online
- Contract term
- five years
- Place of performance
- Onsite or offsite, Washington, DC
Scope of work
- Provide vaccine medical countermeasures, antigens, and adjuvants for public health emergencies
- Produce antigens and vaccines against influenza or other viruses with pandemic potential
- Produce antigens, vaccines, and adjuvants to improve influenza vaccines
- Submit Surge Manufacturing and Supply Chain Readiness Assessments upon COR direction
- Develop, maintain, and submit a comprehensive Business Continuity Plan (BCP)
- Develop, maintain, and submit a Supply Continuity Plan (SCP)
- Develop, maintain, and submit a comprehensive Manufacturing Plan
- Submit a Bill of Materials (BOM) as an attachment to the Manufacturing Plan
Minimum qualifications
- USA Organization Only (Onshore)
Documents to include with the bid
- Surge Manufacturing and Supply Chain Readiness Assessment
- Business Continuity Plan (BCP)
- Supply Continuity Plan (SCP)
- Manufacturing Plan
- Bill of Materials (BOM)
Official SAM.gov notice
- Solicitation number
- 75A50126R00001_RFP_NPIVS_27
- Agency
- Department of Health and Human Services
- Buying office
- Office of Assistant Secretary for Preparedness and Response › Barda - Aspr / Daappo / Barda Dcma
- Notice type
- Solicitation
- Responses due
- Oct 30, 2026, 5:00 PM ET
- Posted on SAM.gov
- Aug 17, 2026
- NAICS
- 541714 · Research and Development in Biotechnology (except Nanobiotechnology)
- Product/service code
- AN12
- Set-aside
- No Set aside used
- Place of performance
- Washington, DC, 20024
- Contracting contact
- Laura Saddison
Laura.Saddison@hhs.gov
Read the official notice description
BARDA seeks Contractor(s) to support the continuation of the Vaccine Medical Counermeasures (MCM's) for Pandemic Influenza Preparedness and Response Program. Contractors will furnish all the necessary services, qualified personnel, materials, supplies, equipment and facilities (U.S. facilities preferred) not otherwise provided by the USG as needed to provide MCMs, such as vaccines, antigens, and adjuvants, for pandemic preparedness and response or as required in response to a public health emergency; produce antigen and vaccines against influenza virus or other viruses with pandemic potential as required by BARDA; produce antigens, adjuvants, and/or vaccines to support USG efforts to further improve influenza vaccines (for which feasibility data is available); and support rapid regulatory decisions and manufacturing readiness by generating and submitting to FDA all relevant data (e.g., analytical, nonclinical, clinical, and/or chemistry, manufacturing, and controls (CMC)), including data generated during interpandemic periods. Mandatory Qualification Requirements: To be eligible for award, the Offeror must produce vaccines against influenza and influenza strains with pandemic potential; must demonstrate a successful experience in the manufacturing of influenza vaccine by: 1. Holding a U.S. influenza vaccine license; or 2. Have developed an influenza vaccine as evidenced by: a. Submission of a Biologics License Application (BLA) for seasonal or pandemic influenza vaccine Please see full solicitation details and proposal submission instructions detailed in attachments 01-19 of this notice.
Source: SAM.gov contract opportunities data (U.S. federal public data).
Incumbent
Likely prior awards for this requirement
Likely matchAwarded by the same buying office (75A501) with descriptions matching "vaccine", performed in DC. The notice does not name its current contract, so confirm before relying on it.
| Vendor and award | Value | Ends |
|---|---|---|
| ADVANCED TECHNOLOGY INTERNATIONAL75A50124F61008 · OT TASK ORDER 8-RAPID PANDEMIC INFLUENZA AND EMERGING INFECTIOUS DISEASE VACCINE DEVELOPME | $418.7M | Sep 16, 2035 |
Market context
Awards in the same category (Research and Development in Biotechnology (except Nanobiotechnology)). This is not this requirement's award history.
Recent similar awards: Department of Health and Human Services, NAICS 541714, performed in DC
| Vendor and award | Value | Ends |
|---|---|---|
| ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)75A50123C00010 · THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE | $163.1M | Sep 30, 2030 |
| MELINTA THERAPEUTICS, LLC75A50123C00022 · ADVANCE THE DEVELOPMENT OF TWO ANTIBIOTICS FOR USE IN THE PEDIATRIC POPULATION FOR THE TRE | $47.5M | Jun 30, 2030 |
| ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)75A50119C00055 · THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBU | $145.4M | Sep 30, 2027 |
| BATTELLE MEMORIAL INSTITUTE75A50125F61004 · USE OF A HUMAN-RELEVANT SMALL ANIMAL MODEL OF SULFUR MUSTARD (SM)-INDUCED INHALATION INJUR | $7.6M | Mar 28, 2027 |
| INFLO MEDICAL INC75A50124C00019 · THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO IMPROVE THE SAFETY METRICS FOR EXTRACORPOREAL | $747.4K | Jun 21, 2026 |
Top vendors in this category: Department of Health and Human Services, NAICS 541714, since Oct 1, 2023
1,469 contract awards in this NAICS over the period.
- 1. ADVANCED TECHNOLOGY INTERNATIONAL$1.6B
- 2. ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)$356.9M
- 3. AMGEN USA INC$345.8M
- 4. START2 GROUP, INC.$223.1M
- 5. PPD DEVELOPMENT LP$197.2M
Source: USAspending.gov federal award data (U.S. federal public data). A contract is called the incumbent only when the notice or its documents cite it by number.
Verify important details
Document checkConfirm submission instructions and amendments with the issuing agency before responding.
Personalized fit score
Sign up free to see how well this opportunity fits your company — based on your saved profile.
Sign up to see your fit score